90 related articles for article (PubMed ID: 23039746)
1. Update on the development of TGR5 agonists for human diseases.
Jin W; Zheng M; Chen Y; Xiong H
Eur J Med Chem; 2024 May; 271():116462. PubMed ID: 38691888
[TBL] [Abstract][Full Text] [Related]
2. Chemical exploration of TGR5 functional hot-spots: Synthesis and structure-activity relationships of C7- and C23-Substituted cholic acid derivatives.
Rosatelli E; Carotti A; Cerra B; De Franco F; Passeri D; Pellicciari R; Gioiello A
Eur J Med Chem; 2023 Dec; 261():115851. PubMed ID: 37813065
[TBL] [Abstract][Full Text] [Related]
3. Discovery of betulinic acid derivatives as gut-restricted TGR5 agonists: Balancing the potency and physicochemical properties.
Zhuo N; Yun Y; Zhang C; Guo S; Yin J; Zhao T; Ge X; Gu M; Xie X; Nan F
Bioorg Chem; 2024 Mar; 144():107132. PubMed ID: 38241768
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and evaluation of 3-phenoxypyrazine-2-carboxamide derivatives as potent TGR5 agonists.
Zhao S; Wang L; Wang J; Wang C; Zheng S; Fu Y; Li Y; Chen WD; Hou R; Yang D; Wang YD
RSC Adv; 2022 Jan; 12(6):3618-3629. PubMed ID: 35425398
[TBL] [Abstract][Full Text] [Related]
5. Discovery, optimization, and evaluation of non-bile acid FXR/TGR5 dual agonists.
Miyata S; Kawashima Y; Sakai M; Matsubayashi M; Motoki K; Miyajima Y; Watanabe Y; Chikamatsu N; Taniguchi T; Tokuyama R
Sci Rep; 2021 Apr; 11(1):9196. PubMed ID: 33911126
[TBL] [Abstract][Full Text] [Related]
6. Bile Acids and GPBAR-1: Dynamic Interaction Involving Genes, Environment and Gut Microbiome.
Portincasa P; Di Ciaula A; Garruti G; Vacca M; De Angelis M; Wang DQ
Nutrients; 2020 Nov; 12(12):. PubMed ID: 33266235
[TBL] [Abstract][Full Text] [Related]
7. GPBAR1 Activation by C6-Substituted Hyodeoxycholane Analogues Protect against Colitis.
Marino S; Finamore C; Biagioli M; Carino A; Marchianò S; Roselli R; Giorgio CD; Bordoni M; Di Leva FS; Novellino E; Cassiano C; Limongelli V; Zampella A; Festa C; Fiorucci S
ACS Med Chem Lett; 2020 May; 11(5):818-824. PubMed ID: 32435390
[TBL] [Abstract][Full Text] [Related]
8. L-Cell Differentiation Is Induced by Bile Acids Through GPBAR1 and Paracrine GLP-1 and Serotonin Signaling.
Lund ML; Sorrentino G; Egerod KL; Kroone C; Mortensen B; Knop FK; Reimann F; Gribble FM; Drucker DJ; de Koning EJP; Schoonjans K; Bäckhed F; Schwartz TW; Petersen N
Diabetes; 2020 Apr; 69(4):614-623. PubMed ID: 32041793
[TBL] [Abstract][Full Text] [Related]
9. Effects of Farnesiferol B on Ischemia-Reperfusion-Induced Renal Damage, Inflammation, and NF-κB Signaling.
Zhang L; Fu X; Gui T; Wang T; Wang Z; Kullak-Ublick GA; Gai Z
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31842453
[TBL] [Abstract][Full Text] [Related]
10. Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives.
Arab JP; Karpen SJ; Dawson PA; Arrese M; Trauner M
Hepatology; 2017 Jan; 65(1):350-362. PubMed ID: 27358174
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a Potent and Orally Efficacious TGR5 Receptor Agonist.
Agarwal S; Patil A; Aware U; Deshmukh P; Darji B; Sasane S; Sairam KV; Priyadarsiny P; Giri P; Patel H; Giri S; Jain M; Desai RC
ACS Med Chem Lett; 2016 Jan; 7(1):51-5. PubMed ID: 26819665
[TBL] [Abstract][Full Text] [Related]
12. A GPBAR1 (TGR5) small molecule agonist shows specific inhibitory effects on myeloid cell activation in vitro and reduces experimental autoimmune encephalitis (EAE) in vivo.
Lewis ND; Patnaude LA; Pelletier J; Souza DJ; Lukas SM; King FJ; Hill JD; Stefanopoulos DE; Ryan K; Desai S; Skow D; Kauschke SG; Broermann A; Kuzmich D; Harcken C; Hickey ER; Modis LK
PLoS One; 2014; 9(6):e100883. PubMed ID: 24967665
[TBL] [Abstract][Full Text] [Related]
13. Probing the Binding Site of Bile Acids in TGR5.
Macchiarulo A; Gioiello A; Thomas C; Pols TW; Nuti R; Ferrari C; Giacchè N; De Franco F; Pruzanski M; Auwerx J; Schoonjans K; Pellicciari R
ACS Med Chem Lett; 2013 Dec; 4(12):1158-62. PubMed ID: 24900622
[TBL] [Abstract][Full Text] [Related]
14. The bile acid TGR5 membrane receptor: from basic research to clinical application.
Duboc H; Taché Y; Hofmann AF
Dig Liver Dis; 2014 Apr; 46(4):302-12. PubMed ID: 24411485
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and structure-activity relationships of amino acid conjugates of cholanic acid as antagonists of the EphA2 receptor.
Russo S; Incerti M; Tognolini M; Castelli R; Pala D; Hassan-Mohamed I; Giorgio C; De Franco F; Gioiello A; Vicini P; Barocelli E; Rivara S; Mor M; Lodola A
Molecules; 2013 Oct; 18(10):13043-60. PubMed ID: 24152675
[TBL] [Abstract][Full Text] [Related]
16. GPBA: a GPCR for bile acids and an emerging therapeutic target for disorders of digestion and sensation.
Lieu T; Jayaweera G; Bunnett NW
Br J Pharmacol; 2014 Mar; 171(5):1156-66. PubMed ID: 24111923
[TBL] [Abstract][Full Text] [Related]
17. Patented TGR5 modulators: a review (2006 - present).
Gioiello A; Rosatelli E; Nuti R; Macchiarulo A; Pellicciari R
Expert Opin Ther Pat; 2012 Dec; 22(12):1399-414. PubMed ID: 23039746
[TBL] [Abstract][Full Text] [Related]
18. Compound and compositions as TGR5 agonists: WO2012082947.
Raval S
Expert Opin Ther Pat; 2013 Apr; 23(4):531-6. PubMed ID: 23409864
[TBL] [Abstract][Full Text] [Related]
19. Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
Sato H; Macchiarulo A; Thomas C; Gioiello A; Une M; Hofmann AF; Saladin R; Schoonjans K; Pellicciari R; Auwerx J
J Med Chem; 2008 Mar; 51(6):1831-41. PubMed ID: 18307294
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
